Amgen to launch Humira biosimilar in 2023 following Abbvie settlement

Amgen on Thursday settled a patent lawsuit with Abbvie over its biosimilar version of Abbvie's best-selling arthritis drug Humira, reports Reuters.

The settlement will delay the launch of Amgen's biosimilar until Jan. 31, 2023, and ends all pending patent litigation between the two drugmakers. Abbvie will also be entitled to royalties on sales of Amgen's biosimilar.

Amgen was the first drugmaker to earn regulatory approval for a Humira biosimilar in Sept. 2016, but refrained from selling the drug during the ongoing patent litigation.

Humira is the highest-selling prescription drug in the world, according to Reuters. The drug generated $4.7 billion in global sales in the second quarter and is on track to exceed $18 billion in annual sales this year. Several other drug companies are still in litigation with Abbvie over their own biosimilar versions of Humira.

More articles on supply chain:

AmerisourceBergen fined $260M over cancer drug packaging: 4 things to know
Millennials least likely to comply with recall notices, study finds
A proactive approach to drug shortages: 6 strategies from Advocate Health Care's director of central service pharmacy

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers